Full Press Release Details
odronextamab bla for treatment of relapsed refractory follicular lymphoma fl and diffuse large b cell lymphoma dlbcl accepted for fda priority review.
REGN
odronextamab bla for treatment of relapsed refractory follicular lymphoma fl and diffuse large b cell lymphoma dlbcl accepted for fda priority review
Key Takeaway: odronextamab bla for treatment of relapsed refractory follicular lymphoma fl and diffuse large b cell lymphoma dlbcl accepted for fda priority review